Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV.
about
Trans-activation of HIV-1 LTR-directed gene expression by tat requires protein kinase CDual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissueAbsolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytesA human primary T-lymphocyte-derived human immunodeficiency virus type 1 Tat-associated kinase phosphorylates the C-terminal domain of RNA polymerase II and induces CAK activityHydroxyurea inhibits the transactivation of the HIV-long-terminal repeat (LTR) promoterThalidomide inhibits the replication of human immunodeficiency virus type 1Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFATCpG methylation controls reactivation of HIV from latency.Identification and characterization of an enhancer in the coding region of the genome of human immunodeficiency virus type 1.Simian-human immunodeficiency virus (SHIV) containing the nef/long terminal repeat region of the highly virulent SIVsmmPBj14 causes PBj-like activation of cultured resting peripheral blood mononuclear cells, but the chimera showed No increase in virTumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone.In vitro activation of the HIV-1 enhancer in extracts from cells treated with a phorbol ester tumor promoter.Good cell, bad cell: flow cytometry reveals T-cell subsets important in HIV diseaseHuman immunodeficiency virus long terminal repeat responds to T-cell activation signals.Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical stagingTranscriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation.Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1 (HIV-1)Interaction of nuclear protein p140 with human immunodeficiency virus type 1 TAR RNA in mitogen-activated primary human T lymphocytes.Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells.Differential susceptibility of naive and memory CD4+ T cells to the cytopathic effects of infection with human immunodeficiency virus type 1 strain LAI.Transforming growth factor beta suppresses human immunodeficiency virus expression and replication in infected cells of the monocyte/macrophage lineage.Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection.Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms.The efficiency of acute infection of CD4+ T cells is markedly enhanced in the setting of antigen-specific immune activation.IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancerEvaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group.Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle.Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping.Direct and cytokine-mediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells.Factors affecting cellular tropism of human immunodeficiency virus."One pill, once daily": what clinicians need to know about Atriplatrade mark.The intragenic enhancer of human immunodeficiency virus type 1 contains functional AP-1 binding sites.The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity.The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursorsDistinct replicative and cytopathic characteristics of human immunodeficiency virus isolates.NF-IL6 (C/EBPbeta) induces HIV-1 replication by inhibiting cytidine deaminase APOBEC3G.Epidemic human immunodeficiency virus (HIV) infection among intravenous drug users (IVDU)Use of cryopreserved normal peripheral blood lymphocytes for isolation of human immunodeficiency virus from seropositive menOptimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells.Microculture assay for isolation of human immunodeficiency virus type 1 and for titration of infected peripheral blood mononuclear cells
P2860
Q24556556-84633402-949D-4BAC-9219-B17063CAE876Q24562082-1AA6390D-85BF-4E31-B26E-A15C77DEA449Q24568326-D95B2FAA-DF69-442A-88E0-2EF07AB2368CQ24671693-0E468315-1F7C-4D7F-AE18-660E448FB991Q28344235-F5E0FDDC-315C-4880-A9F3-8E36ADD86F06Q28378516-D2083D26-35AC-406D-BDBE-A0259D527B1CQ28379490-C17949D2-E17C-4D92-84BB-B5204CD9B6E6Q33495565-4696EBDD-EDA3-4F4E-A314-71184472E898Q33649460-2EAF735C-C697-4FD0-8124-8042AF8893D6Q33784667-F6F3F31A-76CF-4716-852B-7CA004B34AA7Q33847737-DDA539ED-CBEC-49B5-9E57-C56066BB0712Q33930106-4BFCEFC9-BB6C-480C-A72D-7DA857C33A7DQ34007172-222C84BA-219D-4426-8721-4D6DBE34B5E9Q34350307-250646D5-C791-4544-9665-647BE39F374EQ34581195-69076E58-B303-4E6D-AC26-2204361AE484Q34782185-53874062-0B97-4988-9CC3-9DA70FD87E62Q35596389-A7577524-F20A-43FA-95A4-689B37ECFC28Q35845299-7757C306-EF78-4217-AC63-95F9F1940DC6Q35879840-A4CB29B5-45B5-4ABB-A650-2D489179569BQ35886547-B9E3359A-4952-4AF1-92F4-686B52B01727Q36229933-F4D09752-E627-447C-9B47-0ABF7BA8E2EDQ36315149-4B38167F-4272-40BB-B9ED-D82ADCA966CBQ36352092-B251CCD6-7D6D-47E5-8909-2BBF6AE98DF7Q36366278-A066BE92-41D5-4F69-B070-22EB1ED73CEDQ36498248-9E3D2F37-6D5B-4184-8E6E-29F1568FDC1DQ36538361-D4FAAAC3-20A5-4221-945B-E8A8029B1146Q36693174-B019FA6F-9E91-42C3-9065-91BC0CB34EB3Q36780203-0F888C1B-344D-47C0-B396-B436707BF784Q36782918-23FD22E3-FD33-4C13-98D7-242983A5C324Q36793485-9E12DAC1-773D-4381-AC28-2537BAD91510Q36823570-FD17338E-AD50-4052-914D-0F88E4FD74B1Q36829155-639476D0-CABD-4E9F-8E0A-1BDB1A9B040CQ36831819-9A7392BA-43D2-4D1E-A9F7-7AA43435E80AQ36881276-FF555711-25F0-445E-A650-6DD8EC602BAFQ36882975-0CA9FCDA-3E62-458F-AF92-7CCF8611AC53Q36937148-F1D13B1B-A8B9-416E-B8EF-F65355CECC36Q36989554-3FE4530B-7D1F-4C33-A91E-81C48BABC25FQ37145626-B0413049-8226-4D50-8DE0-D84EBA084596Q37158205-82B7428B-6EAC-43B5-A303-B41B4152CC30Q37181442-88AB8ACC-C916-4013-BD31-C94583682E0E
P2860
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh
1986年學術文章
@zh-hant
name
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV.
@en
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV.
@nl
type
label
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV.
@en
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV.
@nl
prefLabel
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV.
@en
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV.
@nl
P2093
P1476
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV.
@en
P2093
Justement J
Redfield R
P304
P407
P577
1986-06-01T00:00:00Z